MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergic neurons"

  • 2022 International Congress

    Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling

    D. Athauda, J. Evans, A. Wernick, G. Virdi, M. Choi, K. D'Sa, Z. Shadman, N. Greig, T. Foltynie, S. Gandhi (London, United Kingdom)

    Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
  • 2022 International Congress

    Protein aggregation and calcium dysregulation are the earliest hallmarks of synucleinopathy in enriched iPSC-derived human midbrain dopaminergic neurons

    G. Virdi, M. Choi, J. Evans, S. Strohbuecker, M. Horrocks, R. Patani, S. Gandhi (London, United Kingdom)

    Objective: Develop and adapt a differentiation paradigm to produce enriched hiPSC-derived midbrain dopaminergic neurons (mDA), to resolve the temporal sequence of pathophysiological events in synucleinopathies.…
  • 2022 International Congress

    Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease

    L. Kou (Wuhan, China)

    Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…
  • 2022 International Congress

    Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease

    B. Muminov, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD. Background: Study of the biochemical aspects…
  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    Glial neurotrophic factor as an early diagnostic marker in Parkinson’s disease

    M. Matmurodov, A. Abduqodirov, L. Khalimova, B. Muminov (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) Background: Glial neutrophic factor (GDNF) is a…
  • 2022 International Congress

    Smoking and Substantia Nigra Neuron Density in the Presence and Absence of Lewy Pathology

    G. Ross, R. Abbott, H. Petrovitch, J. Duda, J. Uyehara-Lock, K. Masaki, C. Tanner (Honolulu, USA)

    Objective: Our objective is to examine the association of mid-life smoking with post mortem substantia nigra (SN) neuron density in the presence and absence of…
  • 2022 International Congress

    In Silico Study Reveals Cocaine Exposure Modulates Dopamine Neuron Firing Patterns by Inhibiting Small Conductance Calcium Activated Potassium Current

    CHI. Mahapatra (Mumbai, India)

    Objective: The neurological reason behind the loss of dopamine neurons causing Parkinson’s disease (PD) is an unsolved mystery. Background: As PD is identified as a…
  • 2022 International Congress

    Clinical Characteristics of patients with Parkinson’s disease showing normal values on SBR in the DAT SPECT

    M. Nomoto, C. Ochi, R. Ando, Y. Murakami (Imabari, Ehime, Japan)

    Objective: The aim of this study was to clarify what the ‘normal’ values of the specific binding ratio (SBR), a measure of striatal radiotracer uptake…
  • 2022 International Congress

    The level of glial neurotrophic factor in blood plasma depending on the stage of Parkinson’s disease

    R. Matmurodov, M. Muminov, A. Abduqodirov, K. Khalimova (Tashkent, Uzbekistan)

    Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) depending on the stage Background: Parkinson's disease…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 17
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley